Studies blood, urine and spinal fluid markers in ALS patients treated with edaravone
Observes markers in people with ALS, some taking edaravone and some not.
Plain-language title generated from the registry record
Registry title: Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone
Key facts
- Where
- Loma Linda, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT04097158, who can take part
Where in United States
- Loma Linda UniversityLoma Linda, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Loma Linda University
- Trial code
- NCT04097158
- Record updated
- 5 June 2026
- Original description
This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS. The investigators are also trying to understand if there are specific ALS patients, with different presentations of ALS, who might benefit most from this medication. Also, the investigators are following specific biomarkers to determine the optimal treatment duration in patients with different forms of ALSRead full original descriptionShow less
Oxidative Markers and Efficacy in Amyotrophic Lateral Sclerosis (ALS) Phenotypes Treated With Edaravone
This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS. The investigators are also trying to understand if there are specific ALS patients, with different presentations of ALS, who might benefit most from this medication. Also, the investigators are following specific biomarkers to determine the optimal treatment duration in patients with different forms of ALS
There is no study medication being offered in this trial. Edaravone is prescribed as part of regular care. In this trial we are collecting blood, urine, and spinal fluid samples in ALS patients who are taking Edaravone and ALS patients who are not taking Edaravone to measure certain markers that could indicate why the drug may be working in a specific type of ALS.
Inclusion: Either possible, probable, or definite ALS, predominantly lower motor neuron disease, predominantly upper motor neuron disease, or bulbar; With or without cognitive involvement; Willing to participate; On no experimental treatment; Ages 18 - 85; No prior exposure to Edaravone (Radicava); On a stable dose of Riluzole for 30 days or off Riluzole; Male or female; Females of childbearing age must use contraception.
Exclusion: Unstable medical illness; Abnormal liver function (>2x ULN); Unlikely to survive for 26 weeks.